Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McKay, Pamela
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	Active, not recruiting	3	500	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa	Loxo Oncology, Inc., Eli Lilly and Company	Lymphoma, Mantle-Cell	12/25	07/26
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL Sep 2021 - Dec 2021 : Submission for r/r DLBCL	Recruiting	3	350	Europe, Canada, Japan, US, RoW	Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin	ADC Therapeutics S.A., ADC Therapeutics SA	Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	06/25	06/28
SYMPHONY-1, NCT04224493 / 2019-003333-42: Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma Additional data from P1b/3 trial in combination with Rituxan for r/r follicular lymphoma at ASH 2021 Dec 2021 - Dec 2021: Additional data from P1b/3 trial in combination with Rituxan for r/r follicular lymphoma at ASH 2021 Safety data from P1b portion of P1b/3 trial in combination with lenalidomide and Rituxan for follicular lymphoma Dec 2021 - Dec 2021: Safety data from P1b portion of P1b/3 trial in combination with lenalidomide and Rituxan for follicular lymphoma Safety data from P1b portion of P1b/3 trial in combination with lenalidomide and Rituxan for follicular lymphoma Mar 2021 - Mar 2021: Safety data from P1b portion of P1b/3 trial in combination with lenalidomide and Rituxan for follicular lymphoma More	Recruiting	3	612	Europe, Canada, US, RoW	Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab	Epizyme, Inc.	Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma	03/26	03/29